Key result
Emerging immunosuppressive therapies in heart transplantation evolve to provide adjunctive options for individualized immunomodulation.
Emerging immunosuppressive therapies in adult heart transplantation are evolving to allow for more individualized, tailored immunomodulatory treatment strategies.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for individualized immunosuppression in heart transplantation; prospective trials required before clinical adoption.
INTRODUCTION: Immunosuppression following heart transplantation has improved graft longevity through the reduction of cellular and antibody mediated rejection. The attempt to limit the unintended consequences of immunosuppressive therapies and address sensitized patients has led to a revolution in immunosuppression. Areas covered: This review will focus on the current emerging immunosuppressive therapies in heart transplantation while reviewing the effective contemporary treatments, and explore the potential development of new immunomodulatory therapies. An exhaustive review of the PubMed database and abstract data from national meetings was performed to compile the data for the manuscript. Expert commentary: The timing and targets of immunosuppressive therapies are evolving to provide adjunctive therapies to the established treatments. Recent advances will allow for further tailoring of immunomodulatory therapies to the individual patient.
No takes yet. Share an insight, caveat, or question.
Furiasse et al. (2016) conducted a review in Heart transplantation. Immunosuppressive therapies was evaluated. Emerging immunosuppressive therapies in heart transplantation are evolving to provide adjunctive treatments and allow for further tailoring of immunomodulatory therapies to the individual patient.
Synapse has enriched 10 related papers. Consider them for comparative context: